Earnings summaries and quarterly performance for scPharmaceuticals.
Executive leadership at scPharmaceuticals.
Board of directors at scPharmaceuticals.
Research analysts who have asked questions during scPharmaceuticals earnings calls.
DT
Douglas Tsao
H.C. Wainwright & Co.
4 questions for SCPH
Also covers: ALKS, APLS, ARGX +19 more
SK
Stacy Ku
TD Cowen
4 questions for SCPH
Also covers: AUPH, BCRX, KALV +3 more
Chase Knickerbocker
Craig-Hallum Capital Group
3 questions for SCPH
Also covers: AVDL, BFLY, BVS +17 more
RC
Roanna Clarissa Ruiz
Leerink Partners
2 questions for SCPH
Also covers: AKBA, AQST, ARDX +5 more
Christian Clark
Leerink Partners
1 question for SCPH
Also covers: XERS
GS
Glen Santangelo
Jefferies
1 question for SCPH
Also covers: ALGN, ANIP, BHC +9 more
Jason McCarthy
Maxim Group
1 question for SCPH
Also covers: BCLI, BRTX, CHRS +10 more
NR
Naz Rahman
Maxim Group
1 question for SCPH
Also covers: ASRT, AYTU, GLMD +3 more
Recent press releases and 8-K filings for SCPH.
Scilex Holding Company Licenses AI Technology for Biotech Exchange
SCPH
New Projects/Investments
- Scilex Holding Company has secured a worldwide exclusive license from Datavault AI for its AI-driven technology to create and operate a Biotech Exchange platform.
- This platform is intended to enable the secure tokenization, trading, and monetization of biotech assets, including genomic, DNA data, diagnostic, therapeutic products, genetic, and drug information.
- The licensing agreement includes a non-refundable upfront license fee totaling $10 million, payable in four equal installments of $2.5 million through September 2026.
- Datavault AI is also eligible for sales milestone payments of up to an aggregate of $2.55 billion upon the achievement of certain sales milestones.
- Scilex believes there is an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug and diagnostic sales through this platform.
Nov 4, 2025, 11:00 AM
scPharmaceuticals Inc. Acquired by MannKind Corporation
SCPH
M&A
Delisting/Listing Issues
Board Change
- scPharmaceuticals Inc. (SCPH) was acquired by MannKind Corporation on October 7, 2025, becoming a direct wholly owned subsidiary.
- Shareholders received $5.35 in cash and one non-tradable contingent value right (CVR) per share, with CVRs potentially yielding up to an additional $1.00.
- Following the acquisition, SCPH shares were delisted from The Nasdaq Global Select Market, and trading was halted on October 7, 2025.
- The company's Board of Directors resigned, and a new management team was appointed, including Michael E. Castagna as President and Chief Executive Officer, and Chris Prentiss as Chief Financial Officer of the surviving corporation.
- Key agreements, including the Credit Agreement and Guaranty and the Revenue Participation Right Purchase and Sale Agreement, were terminated in connection with the merger.
Oct 7, 2025, 1:18 PM
scPharmaceuticals Acquisition by MannKind Completed
SCPH
M&A
Revenue Acceleration/Inflection
Delisting/Listing Issues
- MannKind Corporation completed the acquisition of scPharmaceuticals Inc. on October 7, 2025, making scPharmaceuticals a wholly owned subsidiary.
- The acquisition is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by the innovative therapy FUROSCIX®.
- The transaction was valued at $5.35 per share in cash plus one non-tradable contingent value right (CVR) per share for up to an aggregate of $1.00 per CVR in cash, totaling up to $6.35 per share.
- As of October 7, 2025, scPharmaceuticals' common stock ceased trading and was delisted from Nasdaq.
Oct 7, 2025, 1:02 PM
scPharmaceuticals Investigated by Halper Sadeh LLC Regarding Sale to MannKind Corporation
SCPH
M&A
Legal Proceedings
Takeover Bid
- Halper Sadeh LLC is investigating scPharmaceuticals Inc. (NASDAQ: SCPH) for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders.
- The investigation relates to scPharmaceuticals Inc.'s proposed sale to MannKind Corporation.
- Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share, with the CVR potentially worth up to an additional $1.00 in cash.
Sep 16, 2025, 3:40 PM
scPharmaceuticals Discusses FUROSCIX Performance, Medicare Redesign, and Upcoming CKD Launch
SCPH
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- scPharmaceuticals' FUROSCIX is performing well, with 75% of usage pre-hospitalization and strong patient/physician feedback, while the Class IV patient segment grew to over 10% of patients in Q4 and is expected to reach 25% over time.
- The Medicare redesign (IRA) is anticipated to be a significant growth driver, reducing patient out-of-pocket maximums from $4,000 to $2,000, which is expected to increase fill rates despite an estimated 10-20% rise in Gross-to-Net (GTN) from 18% in 2024.
- The company is preparing for a Chronic Kidney Disease (CKD) indication launch, with a decision expected on March 6, 2025, and a full launch planned for mid-April, which is projected to contribute 35-40% of peak sales from nephrology.
- Development of the SCP-111 auto-injector is on track for a mid-2025 sNDA submission, promising a 70% reduction in COGS and enhanced patient convenience with a two-and-a-half-second administration.
Mar 5, 2025, 4:10 PM
scPharmaceuticals Reports Strong 2024 FUROSCIX Revenue and Anticipates Key Regulatory Approvals in 2025
SCPH
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- scPharmaceuticals (SCPH) reported FUROSCIX net revenue of $12.3 million for Q4 2024 and $36.2 million for the full year 2024, maintaining a strong financial position with $75.5 million at the end of 2024.
- The company anticipates FDA approval for a chronic kidney disease (CKD) indication on March 6, 2025, which is expected to add 700,000 patients and an additional $3 billion addressable market.
- Key growth initiatives include the August 2024 expanded label for Class IV heart failure, a 40% sales force expansion in late October 2024, and the planned mid-2025 submission of an auto-injector which is projected to reduce costs by 70-75% and extend IP to 2040.
- FUROSCIX's value proposition highlights its cost of $4,700 compared to a $15,000 hospitalization, with continued growth expected from Medicare redesign reducing patient out-of-pocket costs in 2025.
Feb 12, 2025, 7:40 PM
scPharmaceuticals Highlights Furoscix Performance and Future Growth Drivers
SCPH
Product Launch
Revenue Acceleration/Inflection
Guidance Update
- scPharmaceuticals (SCPH) reported unaudited net revenue of approximately $12.3 million for Q4 2024 and $36.2 million for the full year 2024 for its product Furoscix. The company maintained a strong financial position with approximately $75.5 million at the end of 2024.
- Significant growth initiatives for 2025 include an anticipated FDA approval for chronic kidney disease (CKD) on March 6th , which is expected to add 700,000 patients and a $3 billion additional addressable market.
- The company plans to submit an auto-injector for Furoscix later in 2025, which is projected to reduce costs by 70-75% and extend intellectual property to 2040.
- Other growth drivers include an expanded label for Class IV heart failure approved in August 2024 , a 40% increase in the sales force in late October 2024 , and Medicare redesign in 2025 that reduces patient out-of-pocket costs by approximately 40%.
Feb 12, 2025, 7:40 PM
Quarterly earnings call transcripts for scPharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more